XML 25 R4.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Net sales $ 1,741.0 $ 1,532.2 $ 3,389.6 $ 2,944.9
Cost of sales 392.4 344.4 755.0 646.0
Gross profit 1,348.6 1,187.8 2,634.6 2,298.9
Selling, general, and administrative expenses 561.2 502.0 1,083.4 967.7
Research and development expenses 278.9 276.2 542.2 530.8
Certain litigation expenses 6.3 15.5 43.4 26.4
Separation costs 0.0 4.2 0.0 8.4
Other operating income (11.0) (21.3) (25.2) (40.4)
Operating income, net 513.2 411.2 990.8 806.0
Interest income, net (30.0) (37.4) (63.5) (73.9)
Loss on impairment (Note 6) 40.0 47.1 163.6 47.1
Other non-operating (income) expense, net (Note 7) (16.6) 1.3 (88.1) (1.3)
Income from continuing operations before provision for income taxes 519.8 400.2 978.8 834.1
Provision for income taxes 278.4 64.3 356.7 134.6
Net income from continuing operations 241.4 335.9 622.1 699.5
Loss from discontinued operations, net of tax 0.0 (4.4) 0.0 (11.6)
Net income 241.4 331.5 622.1 687.9
Less: Net loss attributable to noncontrolling interest (0.5) (1.7) (0.5) (3.3)
Net income attributable to Edwards Lifesciences Corporation $ 241.9 $ 333.2 $ 622.6 $ 691.2
Basic        
Continuing operations (in dollars per share) $ 0.42 $ 0.58 $ 1.08 $ 1.20
Discontinued operations (in dollars per share) 0 (0.01) 0 (0.02)
Basic earnings per share (in dollars per share) 0.42 0.57 1.08 1.18
Diluted        
Continuing operations (in dollars per share) 0.42 0.57 1.07 1.20
Discontinued operations (in dollars per share) 0 (0.01) 0 (0.02)
Diluted earnings per share (in dollars per share) $ 0.42 $ 0.56 $ 1.07 $ 1.18
Weighted-average number of common shares outstanding:        
Basic (in shares) 576.4 587.0 577.8 586.9
Diluted (in shares) 577.6 587.9 579.2 587.9